Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

NeoGenomics won summary judgment against Natera in patent infringement litigation in the U.S. District Court for the Middle District of North Carolina. The court ruled that all of Natera's asserted patent claims are invalid for claiming ineligible subject matter and will dismiss Natera's claims with prejudice while entering declaratory judgment of invalidity for both patents. The ruling allows NeoGenomics to continue commercializing its RaDaR ST molecular residual disease assay without restriction. NeoGenomics has launched the assay to biopharma customers and submitted it for CMS reimbursement coverage.